1stOncology™: Cancer Intelligence Service – Page 15918 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting

On December 4, 2017 Seattle Genetics, Inc. (NASDAQ:SGEN) reported that the company will webcast an investor and analyst event on Monday, December 11, 2017 during the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in Atlanta, GA (Press release, Seattle Genetics, DEC 4, 2017, View Source;p=RssLanding&cat=news&id=2320818 [SID1234522352]). Industry experts will discuss the ADCETRIS (brentuximab vedotin) phase 3 ECHELON-1 data, and members of the Seattle Genetics management team will discuss other program highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The event will take place from approximately 8:30 p.m. to 9:30 p.m. Eastern Time. The webcast will be available live and for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

On December 4, 2017 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn ‘cold’ tumors ‘hot’, reported that it will present at the Oncolytic Virotherapy Summit (Press release, Oncolytics Biotech, DEC 4, 2017, View Source [SID1234522351]). Dr. Matt Coffey, Oncolytics’ President and Chief Executive Officer, will present on Wednesday, December 6 at 11:00 a.m. ET as part of a panel presentation and then present specifically on pelareorep in a Clinical Case Study presentation at 2:30 p.m. ET on the same day. The conference takes place on December 5th, 6th and 7th in Miami, Florida.

"The Oncolytic Virotherapy Summit offers us another opportunity to highlight our extensive experience with pelareorep in the clinic and to illustrate its ability to induce an inflamed tumor phenotype amongst our peers and for potential partners," said Dr. Coffey. "Our clinical experience with pelareorep has led us to favorable feedback from the FDA following our end-of-phase 2 meeting which helps us define a clear regulatory path in metastatic breast cancer and a single 400-patient phase 3 registration study. Our phase 3 protocol will be made available following evaluation and completion of discussions with clinical advisors, potential partners and the EMA."

The panel presentation: "How Can We Improve The Efficacy of Oncolytic Virotherapies?", also including management from PsiOxus Therapeutics, Vyriad and Replimune Group, will cover:

Viral modulation of the tumor microenvironment
Increasing the viral impact with activated immune responses
Combination drug therapies to stimulate the immune response and prevent immunosuppression
Viral delivery for largest impact
Dr. Coffey’s individual presentation: "Clinical Progress and Robust Safety Findings of Using Reovirus as an Immuno-Oncology Viral Agent to Treat Cancer", will highlight:

The role of REOLYSIN in the activation of the immune system and the induction of an inflamed tumor phenotype in the tumor microenvironment
Overall survival data from the Company’s randomized phase 2 metastatic breast cancer study
The largest pooled safety database of any oncolytic virus
About REOLYSIN/Pelareorep
REOLYSIN, also known as pelareorep, is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.

NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology

On December 4, 2017 NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, reported an oral presentations will be given at the upcoming 59th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Atlanta, Georgia on Saturday, December 9, 2017 (Press release, NantKwest, DEC 4, 2017, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2320823 [SID1234522350]).

Presentation Title

CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel "Off the Shelf" Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and a Human Lymphoma Xenograft Model Target Activated Natural Killer (CD19.taNK) Cellular Therapy: A Novel Immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL)

Abstract #110: View Source

Presenter: Sneha Purvey, MD, Department of Hematology and Oncology, Tufts Medical Center, Boston, MA

Date: Saturday, December 9, 2017, 9:45AM, Building C, Level 1, C101 Auditorium (Georgia World Congress Center)

Presentation Summary

This oral presentation will present preclinical data on the company’s CD19.taNK program. CD19.taNK cell therapy is based on the use of engineered NK cells expressing a human anti-CD19 CAR that target CD19 expressing cells. The study was designed to more deeply understand the mechanism of action associated with NK-based therapy in B cell NHL and determine the potential for CD19.taNK cells as an "off the shelf" therapy.

The study author’s identified high levels of NK activating ligands indicative of a conserved mechanistic response to CD19-CAR NK cell therapy. In addition, the authors determined that CD19.taNK cell therapy induced significant single-agent cytolytic activity against a wide range NHL cells, including primary DLBCL cells, and cells resistant to standard anti-CD20 antibody.

"CD20 targeted antibody therapy represent one of the most effective and widely used therapeutic interventions in blood cancers. However, resistance is common, occurring in a large percentage of patients," said Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. "For next generation therapies, such as our CD19.taNK cell therapy, circumventing resistance requires both a deeper understanding of the mechanisms of resistance and the mechanisms of action. We believe these study results provide encouraging data elucidating the significant, single-agent cytolytic activity of CD19.taNK cell therapy and takes us one step closer in our focus to transition this novel NK cell therapy to clinical cancer care."

Abbott to Present at J.P. Morgan Healthcare Conference

On December 4, 2017 Abbott (NYSE: ABT) reported that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8, 2018 (Press release, Abbott, DEC 4, 2017, View Source [SID1234522346]). Brian Yoor, executive vice president of finance and Chief Financial Officer, will present at the conference at 6 p.m. Central time.

A live audio webcast of the presentation will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com. An archived edition of the presentation will be available the next day.

Vernalis plc enters into research collaboration with Daiichi Sankyo

On December 3, 2017 Vernalis plc (LSE: VER) reported that it has entered into a drug discovery collaboration with Daiichi Sankyo Company, Limited utilizing Vernalis’ fragment and structure-based drug discovery platform against undisclosed oncology targets (Press release, Vernalis, DEC 3, 2017, http://www.vernalis-research.com/respubs/research-press-releases/729-vernalis-plc-enters-into-research-collaboration-with-daiichi-sankyo [SID1234531525]).

The financial terms of this collaboration are not disclosed.

Ian Garland, CEO of Vernalis, commented: "We are delighted to be working with Daiichi Sankyo on this project. This is another excellent endorsement of our market leading fragment and structure-based drug discovery platform and we look forward to a successful collaboration with Daiichi Sankyo."